CCIA
MRSN

Campbell & Co Investment Adviser’s Mersana Therapeutics MRSN Stock Holding History

Campbell & Co Investment Adviser’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-478
Closed -$81K – 916
2022
Q3 		$81K Buy
+478
New +$77.7K 0.02% 684

Other funds holding MRSN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Campbell & Co Investment Adviser's MRSN Position: Q4 2022 in Review

Campbell & Co Investment Adviser sold out of Mersana Therapeutics (MRSN) in Q4 2022, closing a stake of 478 shares — an estimated $81K sold.

Campbell & Co Investment Adviser first reported a position in MRSN in Q3 2022 and held it in 1 quarter. The position peaked at $81K in Q3 2022. 152 funds tracked by Wall St. Rank hold MRSN as of Q4 2022.

  • Campbell & Co Investment Adviser reported no remaining Mersana Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 478 Mersana Therapeutics shares in Q4 2022, an estimated $81K.
  • Campbell & Co Investment Adviser first reported a position in Mersana Therapeutics in Q3 2022 and held it in 1 quarter.
  • Campbell & Co Investment Adviser's Mersana Therapeutics position peaked at $81K in Q3 2022.
  • 152 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2022.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2022, filed 14 Feb 2023.